Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Explore affordable index funds for retirement and learn how low fees can boost your long-term gains. This intro covers selection basics and cost considerations.
23,808 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
A newly launched XRP ETF promises to deliver twice the daily moves of XRP, inviting traders to pursue a quick double ...
In March 2026, Anduril landed a long-term Army contract valued up to $20 billion, moving defense tech from pilots to ...
Bitcoin built on recent gains as macro risk appetite improved and liquidity returned, setting the stage for a test of...
NVIDIA still leads the AI chip race, but investors are spreading bets downstream to adjacent AI opportunities as the ...
Ripple announces a security collaboration with Crypto ISAC to share North Korea-linked threat intel, aiming to streng...
Chrome is quietly shifting how it handles data with a big on-device AI move and a loosened privacy pledge. This in-de...
Nvidia sits at the center of AI, and May 20 earnings looms large. This guide breaks down whether you should Nvidia st...
Bitcoin faces a potential surge as AI arms spending and geopolitical risks boost liquidity. arthur hayes predicts rac...
A leaked briefing describes a government-linked AI model that reportedly forecasts a sharp Bitcoin rally by the end o...
Poet Technologies sank today, sparking questions about its future. This analysis breaks down what happened, what it m...
KeyBanc boosts Okta's target to $103 from $95, citing a brighter security spending outlook and the central role of id...